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As countries reform their patent laws to be in compliance with the Trade Related Intellectual Property
Rights Agreement, an important question is how increased patent protection will affect drug prices
in low-income countries. Using pharmaceutical trade data from 1996 to 2005, we examine the role
of China and India as suppliers of medicines to other middle- and low-income countries and evaluate
the competitive effect of medicine imports from these countries on the price of medicines from high-
income countries. We find that imports of antibiotics and unspecified medicaments from India and
China significantly depress the average price of these commodities imported from high-income trading
partners, suggesting that India and China are not only important sources of inexpensive medicines
but also have an indirect effect by lowering prices through competition. As India is the leading supplier
of medicines in Sub-Saharan Africa, this region will likely be affected most adversely.
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Introduction 
 
The World Health Organization (WHO) cites high medicine prices and the underuse of 
generics  as  a  major  inefficiency  in  national  health  systems  (WHO,  2010).  High  prices  can  be 
particularly burdensome to the poor in developing countries, many of who live on less than 1 USD 
per day and pay for medicines and health services out-of-pocket. Approximately one third of the 
global population lacks reliable access to medicines because they cannot afford to purchase them 
(WHO, 2004). A recent study has shown that purchasing selected medicines out-of-pocket has the 
potential to push a significant proportion of the population into poverty (Niëns et al., 2010). High 
medicine prices are also a burden on government budgets, with medicines accounting for about 25% 
of national health care budgets in developing countries as a whole (WHO, 2003).   
Generic medicines have proven to be a cost-saving alternative to more expensive branded 
equivalents (Lexchin, 2004). Developing countries, such as Brazil and India, have developed drug 
manufacturing capacity and have emerged in the last decade as important sources of inexpensive 
generic medicines for their domestic and regional consumers. India, for example, is often cited as 
the lead source of inexpensive antiretroviral medicines that have helped to revolutionize HIV/AIDS 
treatment in Sub-Saharan Africa. Given the anecdotal evidence regarding the importance of some of 
these countries as suppliers of cheaper medicines, this paper attempts a systematic evaluation of the 
importance of middle-income countries as suppliers of affordable medicines to other developing 
countries. 
The issue of access to affordable medicines is particularly salient given the implementation 
of the Trade Related Intellectual Property Rights Agreement (TRIPS), which requires all members of 
the World Trade Organization to guarantee intellectual property rights protection for 
pharmaceuticals. Prior to the ratification of the TRIPS, many developing countries allowed very 
little, if any, intellectual property rights protection for pharmaceutical products (Barton, 2004).    4 
Many countries have since reformed their patent laws to be in compliance with the TRIPS and now 
grant patents for new medicines (Arvind, 2004; Scherer & Watal, 2002). One possible implication of 
this change in patent policy is that developing countries with an active generic drug industry will be 
unable to continue copying innovative drugs from the developed world. This may decrease the 
availability of affordable drugs for poor consumers in developing countries. However, in order to 
fully assess the impact of such policy changes, we need to know the extent to which these countries 
matter as a source of medicines for developing countries.  
The  purpose  of  this  paper  is  two-fold:  it  explores  the  role  of  middle-income  countries, 
particularly China and India, as suppliers of medicines to other middle- and low-income countries; 
and  it  examines  the  competitive  effect  of  drug  imports  from  these  countries  on  the  price  of 
medicines  imported  from  high-income  trading  partners.  Using  the  assumption  that  firms  in 
developing countries are primarily involved in imitative drug production, we exploit the variation in 
trade with developing countries across time and pharmaceutical commodity classes to determine the 
price impact of pharmaceutical products exported by China and India.   
 
The Global Pharmaceutical Market  
Developing countries tend to run a trade deficit on pharmaceuticals because most countries 
lack manufacturing and innovative capability. They therefore depend on imports for their domestic 
supply of medicines.  Local pharmaceutical industries in developing countries, when they exist, tend 
to be small and focused on the production of traditional medicines or generic medicines for 
domestic consumption.  Some middle-income countries are an exception to that trend. Argentina, 
Brazil, China, Cuba, India, Mexico and South Africa, for example, have domestic pharmaceutical 
industries with varying levels of innovative capability (Balance, 1992). India and China are important 
suppliers of medicines, particularly in products such as antibiotics and ARVs that treat diseases   5 
prevalent in developing countries. India produces both active ingredients and final products and is 
among the leading suppliers of antiretrovirals to developing countries. The government 
Pharmaceutical Organization in Thailand, for example, sources 90% of its materials for ARV 
production from India and produces ARVs that are up to 25 times cheaper than their branded 
equivalent.  The Thai Public Health Ministry acknowledges that these savings would have been 
impossible without the Indian supply (Grace, 2004). China is also a major supplier of ingredients for 
antibiotics and has been ranked as the leading producer of penicillin, doxycyclin hydrochloride, 
cephalosporin and teramycin, producing more than 50% of the global supply (Grace, 2004).   Brazil 
is regarded as a leader in its successful response to the HIV/AIDS epidemic which was partially 
facilitated by domestic production of generic antiretrovirals (Flynn, 2008). Pharmaceutical 
production capabilities in Africa are far less developed but the situation is likely to improve with 
recent initiatives by the African Union and the United Nations Industrial Development 
Organization (UNIDO) to strengthen local production (Berger et al., 2010). South Africa is the only 
country with the ability to manufacture active pharmaceutical ingredients and account for 70% of 
the estimated $1 billion in annual pharmaceutical production in Sub-Sahara Africa. Ghana, Nigeria 
and Kenya are also regional players but to a lesser extent.  
The ability of these countries to develop their generic industry has been facilitated by their 
patent laws that, prior to TRIPS, did not allow patent protection for pharmaceuticals. India’s weak 
intellectual property protection, for example, helped to facilitate the development of its local 
pharmaceutical industry (Grace, 2004; Lanjouw, 1998; Kettler & Modi, 2001; Watal, 2000). After 
India’s 1970 patent law reforms, the government allowed patents for the manufacturing process but 
not the final product. This allowed companies to legally reverse engineer patented products 
developed in high-income countries and provide cheaper generic copies produced using a different 
process.   6 
TRIPS, which was signed at the Uruguay Round of the World Trade Organization (WTO) 
negotiations in 1995, establishes the framework for the protection of intellectual property 
protection.  Article 27 requires that all WTO members guarantee at least 20 years of market 
exclusivity for patented medicines. Brazil amended its patent laws to become TRIPS-compliant in 
1996. China and India took similar steps in 1999 and 2005 respectively. The public health 
implications of TRIPS have been extensively discussed in the literature (see for example: Barton, 
2004; Commission on Intellectual Property Rights Innovation and Public Health, 2006; Shadlen, 
2007; Smith, Correa, & Oh, 2009; Trouiller et al., 2002).  The issue of access to affordable medicines 
has gained particular attention with the primary concern being TRIPS-compliance will eliminate the 
supply of affordable generic medicines, in particular copies of drugs still on patent, for poor 
consumers in low- and middle-income countries.  It is also likely that enhanced intellectual property 
protection will incentivize domestic firms to invest in R&D, as preliminary evidence in India 
suggests (Lanjouw & Cockburn, 2001).  However, it is not clear whether these firms are likely to 
invest in products that target the health problems of the developing world or those of high-income 
countries. Emerging evidence suggests that TRIPS compliance has changed the incentives for Indian 
firms who are shifting their focus to R&D and high-income markets (Chaudhuri et al., 2010; 
Shadlen, 2007). The emergence of TRIPS-plus, which tends to have even more stringent 
requirements for intellectual property rights protection embedded in bilateral free-trade agreements, 
has made the potential effects of TRIPS on access to medicines even more unclear and contentious 
(Smith, Correa, & Oh, 2009).  As such, a systematic evaluation of the role of middle-income 
countries as medicine suppliers is a necessary precursor in studying the impact of TRIPS on access 
to medicines.  
 
   7 
Patents, Generic Competition and Medicine Prices 
For most commodities, one of the most important determinants of price is the marginal cost 
of production.  In the case of pharmaceuticals, however, variations in marginal costs are unlikely to 
affect the prices of drugs, particularly patent-protected branded drugs (Scherer, 2004). There are 
very high fixed costs associated with the discovery and development of new a new drug but the 
marginal costs of production are very low. The high fixed costs, which need to be recovered, dictate 
the price of the drug more so than the marginal costs. Danzon (1998), for example, estimated that 
fixed costs comprised 70% of pharmaceutical costs while manufacturing and short-run costs 
accounted for the remaining 30%. The fixed costs for generic drug production are much lower than 
those for innovative drugs because the high fixed costs associated with R&D are reduced as the 
innovation has already been achieved.  Marginal costs are also reduced because of lower production 
costs for generic firms in developing countries. Generics are therefore expected to be cheaper than 
branded drugs, but the price for any given drug will be more strongly determined by fixed costs 
instead of marginal costs.  
International reference pricing, a practice in which the price of a ‘basket’ of pharmaceutical 
products in one or more countries is used to set a benchmark price for the same product in a given 
country, is often a key determinant of medicine prices (Epsin et al., 2011). However, the method for 
calculating prices varies across countries depending on regulatory capabilities, the reference 
countries chosen and the basket of goods chosen for comparison. So even with this price 
benchmarking, price differentials exist both across countries and across different groups of 
consumers in a given country. Further, firms usually engage in price discrimination, an important 
factor that affects the price differences. Drug firms face two markets, one (typically in low-income 
countries) where consumers are price sensitive and seek the lowest cost possible, and another 
(typically in high-income countries) where consumers are fairly price insensitive and are willing to   8 
pay more. While the firm may choose setting a high, uniform price to target the price insensitive 
consumers, more commonly, firms choose to price discriminate to capture as much of each market 
as possible (Ridley, 2005).  Therefore prices of pharmaceuticals are expected to vary with the ability 
to pay across countries. There is evidence of this in the preferential pricing practices among 
multinational pharmaceutical firms (Lichtenberg, 2010). The least developed countries are usually 
sold medicines at lower prices compared to richer countries. 
Intellectual property rights protection is a major incentive for innovation in the 
pharmaceutical industry and is a key determinant in medicine pricing. Innovative medicines with 
patent protection are granted limited market exclusivity within the jurisdiction of the patent, which 
limits the legal competition to therapeutic equivalents in a different brand.  For products with no 
therapeutic equivalent and that are protected by a patent, the manufacturer can price the drug as 
high as the market will bear. Upon patent expiration, these medicines usually face competition from 
generic versions, which are therapeutically equivalent.   
Copies of on-patented innovative drugs may also be marketed before patent expiration but 
the legality of these generics will vary depending on patent jurisdiction. Prior to the ratification of 
the TRIPS, many developing countries allowed very little, if any, intellectual property rights 
protection for pharmaceutical products (Barton, 2004).  Many countries have since reformed their 
patent laws to be in compliance with the TRIPS and now grant patents for new medicines (Arvind, 
2004; Scherer & Watal, 2002).  Least developed countries have until 2016 to implement these 
changes. Given this gradual reform of the patent laws across countries, it is expected that the same 
drug may face different competition from generics depending on whether or not patents are allowed 
in a given jurisdiction.  This competition is limited to the extent that the given country has local 
manufacturing capability and/or allows importation of generics from other countries with such 
capability. The local industry, where it exists, can respond to local and regional health needs to the   9 
extent that the trade and patent laws allow the legal copying of innovative drugs. In Brazil, for 
example, local generic manufacturers have decreased the cost of anti-retroviral drugs by more than 
70% (Samb, 2003). 
The entry of generics will follow one of two price trajectories (Scherer, Anthony, & 
Newhouse, 2000).  Initial generic entry will lead to the price of generics being slightly less than 
average of the brand name drugs.  As more generic brands enter the market, competition develops 
from just generics versus branded drugs to include competition among generic brands, which may 
cause the average price of generics to decrease more substantially.  In a developed country where 
consumers can afford to pay or rely on insurance coverage, the branded drug firm may find it more 
profitable to serve the market preferring the branded drug and maintain their high prices instead of 
decreasing prices to compete with generics.  In the developing world, however, where there is such a 
high inability to pay, the branded drug firm may find it more profitable to decrease prices to 
compete with the generics (Danzon & Towse, 2003; Ridley, 2005).  
In developing countries, concerns over TRIPS are often with drugs that are still on patent, 
meaning that western generic versions for those drugs are unavailable. The generic version of 
branded on-patent drugs are therefore likely to only be sourced from middle-income countries like 
India and Brazil, which up until recently did not grant patents for pharmaceutical products. The 
presence of generic drugs competition from these middle-income countries is therefore likely to be a 
chief determinant of pharmaceutical prices in developing countries. Thus, in addition to evaluating 
the importance of select middle-income countries as sources of medicines, another primary objective 
of this paper is to investigate the effect of the share of pharmaceutical imports from these countries 
on the price of pharmaceutical imports from high-income trading partners. A key assumption here is 
that the drugs marketed by developed countries are either patented branded drugs or generic copies 
of drugs that have gone off patent (WHO, 2004). Developing countries on the other hand may   10 
market generics of two kinds: those that are copies of drugs that are still on patent and generics that 
are copies of branded drugs that have gone off patent.   
On average, it is expected that generics of off-patent drugs are likely to be the same in terms 
of price whether the drug is being marketed by firms from developed or developing countries.  
Ideally, the focus should be on the other type of generics, those that are copies of drugs that are still 
on patent, as they will present the biggest cost differential between generics and branded versions. 
Further, it is for this group of generics that trade from developing countries with manufacturing 
capability are expected to be different and most relevant to the implication of TRIPS on the 
affordability of medicines. Unfortunately, the available data do not allow for differentiation between 
these two types of generics.
1 We therefore assume that, on average, drugs marketed by developing 
country firms are generic copies of branded drugs while drugs offered by firms from developed 
countries are innovator brands. If this is the case, it is expected that the importation of generics 





  Three different types of data were used in this study: patent, trade, and economic 
development indicators. Patent data were obtained from Delphion, a fee-based patent search service, 
and the free-access database of the European Patent Office. The patent data were used for two 
purposes: to identify the innovative developing countries to be used in the regressions for evaluating 
the effect of trade; and to examine the patenting trends of innovators from high-income countries in 
developing countries for which data are available.
3 The International Patent Classification (IPC) 
provides a hierarchical system in which technologies are divided into various groups. There are two 
major subclasses of patents that classify pharmaceuticals, A61K and A61P.  Subclass A61K classifies   11 
pharmaceutical compounds based on their chemical structure while A61P classifies compounds 
according to their therapeutic activity. Patent data were downloaded with the search restricted to 
subclass A61K excluding the patent groups that relate to veterinary medicine, cosmetics and 
dentistry (A61K 5/00, 6/00, 7/00, 8/00).
4 These data were used to generate patent counts based on 
the inventor’s country. Inventors need to file patent applications in each jurisdiction where they 
desire patent protection. We examine the patenting activity of pharmaceutical innovators, 
particularly from high-income countries. 
  The data on trade in pharmaceuticals are from the United Nations Statistical Division 
Commodity Trade database (ComTrade) and the analysis is limited to the years 1995 to 2005. They 
were used to examine trends in pharmaceutical trade. These trade data were also used along with 
variables derived from the World Bank’s Development Indicators (WDI) in the regression analyses. 
The  ComTrade database uses the Harmonized Systems (HS), which is a six-digit internationally 
standardized nomenclature used for classifying traded commodities.  The trade values of exports and 
imports between participating countries are recorded for different commodities in US dollars and 
various quantity measures. Chapter 30, which deals specifically with pharmaceuticals, has six 
headings at the 4-digit level.  Only subheadings (six-digit level) under headings 3002, 3003 and 3004 
are considered for the purposes of this research as they classify medicinal preparations for 
prophylactic or therapeutic uses.  This results in 15 different commodity classes that codify active 
ingredients and finished products at the 6-digit level. We combined these 15 classes into 7 
commodity groups for analysis as shown in Table 1.  
 
[Table 1 about here] 
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For each trade event, both the exporter and the importer provide a report of the trade. We 
used the importer-reported values because we use trade value and quantity to calculate price per 
kilogram as a proxy for base market price in the importing country. The importer-reported trade is 
therefore more suitable. The importer-reported value includes the transaction value of the goods, 
the quantity of goods in kilograms, the value of services performed to deliver the goods to the 
border of the exporting country and to the border of the importing country.
5 The data do not allow 
us to identify specific manufacturer brands, nor do they allow us to identify specific medicines and 
their therapeutic classes. Second, the reported trade values do not represent the final purchase price 
of the drug for a consumer. Additional taxes, local distribution costs and other retail markups also 
help to determine the final purchase price. However, it is reasonable to treat the import value as an 
indicator of aggregate base price before additional markups. The mean price per kilogram for a 
pharmaceutical commodity from a given country can therefore be assessed based on the recorded 
trade value and quantity. A primary advantage of using the trade data is that they allow us to 
associate an approximated cost of pharmaceutical commodities with their country of production.  
   
Trends in Patents and Trade 
  The trends in the patent data show that innovative capacity for pharmaceuticals has increased 
tremendously since the 1990s for some developing countries (Fig. 1). While there is no clear 
threshold indicating the point where the industry becomes innovative, it is clear from Figure 1 that 
there is an increasing trend among these countries in the number of US-granted pharmaceutical 
patents.
6  There are two apparent groups of countries with India and China as the clear leaders. Both 
India and China show a similar trend of explosive growth after 1993 with India surpassing China 
and leading in total patent count in 1997 and thereafter (Fig. 1).  The second group includes South   13 
Africa, Argentina, Brazil, Mexico and Cuba which showed an increase in patent applications starting 
in 1994 and which has remained constant on average but higher than their respective counts in the 
1980s. These trends are consistent with the typology described by Ballance and colleagues (1992), 
which cites these developing countries among those that have a pharmaceutical industry with some 
level of innovative and reproductive capability.  
 
[Figure 1 about here]   
   
  Of the seven countries included in Figure 1, we only have a close to full panel of data for 
patents granted domestically in Brazil and India.
7  As Figure 2 shows, pharmaceutical patents 
granted in Brazil increased exponentially starting in 1997.  This increase coincides with the 
introduction of Brazil’s new TRIPS-compliant patent law, which allows patenting of pharmaceutical 
products.  Note that inventors need to file separate patent applications in each patent jurisdiction 
where they need intellectual property protection. The increases in granted patents in Brazil are not 
surprising but note that patents to US inventors increased exponentially relative to the other leading 
innovators.  The introduction of the new law changed patenting behavior among the leading 
inventors and allowed innovators from countries like the US to strengthen the intellectual property 
protection of their products in Brazil.   
 
[Figure 2 about here] 
 
The trends in India are different from those observed for Brazil. Unlike Brazil, India did not 
make its patent laws TRIPS-compliant until 2005. As Figure 3 shows, pharmaceutical patent grants 
started to increase in India in 1992. Domestic patents account for much of the increase and the 
number of patents granted to the leading pharmaceutical innovating countries remain fairly constant   14 
for much of the period. While there was a slight increase in the patent counts for the US, its counts 
remained relatively low and stable compared to that of the domestic patents granted in India. So 
while producers from the innovative high-income countries account for much of the increase in 
granted patents in Brazil, much of the increase in granted patents in India were to local producers.  
Note that this increase in patents in India started before TRIPS-compliance and therefore likely 
indicates the growth of the local generic industry.  
 
[Figure 3 about here] 
 
   
Much of the trade activity in pharmaceuticals is attributable to just two commodity groups, 
antibiotics and unspecified medicaments. Unspecified medicaments account for 85% of exports 
from high-income countries, antibiotics account for 6% and vitamins account for 5%. On average 
unspecified medicaments account for 75% and antibiotics account for 15% of exports from 
Argentina, Brazil, China, India and Mexico. This is not surprising as these two groups include the 
broadest classes of medicines for both chronic and infectious diseases. They also include 
antiinfectives such as antibiotics and antiretrovirals, which are particularly relevant in some 
developing country markets. 
The polarization of the global pharmaceutical market is reflected in Figure 4, which shows 
that high-income countries tend to trade among themselves with 77% of pharmaceutical export 
volume for the period 1996 to 2005 going to other high-income countries. Europe and Central Asia 
represented only 9% of the trade volume for that same period with the remaining volume almost 
equally divided between the other regions. This pattern aligns with income-level and is consistent 
with what is known about the global pharmaceutical market. High-income countries have a higher 
purchasing power and pharmaceutical consumption rates and therefore account for the bulk of the 
global pharmaceutical market.    15 
 
[Figure 4 about here] 
 
There is also some notable variation in the destination of the pharmaceutical exports from 
Argentina, Brazil, China, India and Mexico. The majority of the exports from Argentina and 
Brazil—95% and 96% respectively—were traded with other countries in the Latin American region 
(Fig. 4). Thirty nine percent of the exports from Mexico are traded with high-income countries, 
primarily the US, but the majority of its export is also traded within the region. The export trends 
for the Latin American countries are in contrast to those of India and China, which have more 
diverse regional markets (Fig. 5 & 6). What is most notable about the case of China is that exports to 
high-income countries remained relatively stable between 1996 and 2005 while exports to both Sub-
Saharan Africa and Asia Pacific increased during that period from 3 to 15 and 10 to 18 million 
kilograms respectively (Fig. 5). India also had increases in its exports to all regions during that period 
but particularly to Sub-Saharan Africa and high-income trading partners (Fig. 6). Much of the 
increase began in 1999 with exports to Sub-Saharan Africa increasing from approximately 20 to 50 
million kilograms between 1999 and 2006. On average, only 26% of India’s pharmaceutical exports 
were traded with high-income countries, 35% was traded with Sub-Saharan African countries, 16% 
with Asia and Pacific countries and 14% with Eastern and Central Europe (Fig. 4). Since 2000, 
India’s share of exports to Sub-Saharan Africa has exceeded the amount traded with all other 
regions.  
We also examined the import trends across the different regions to see whether there is 
variation in the reliance on Argentina, Brazil, China, India and Mexico as sources of pharmaceutical 
products. Figure 7 shows the patterns in regional imports. With the exception of the Sub-Saharan 
Africa region, high-income countries are the major source of pharmaceutical imports for developing   16 
countries between 1996 and 2005. This is particularly evident in the Middle East and North Africa 
Region which received an average of 88% of its imports from high-income countries for the entire 
period. The lowest averages were in Latin America and Sub-Saharan Africa where imports from 
high-income countries represented only an average share of 53% and 33% respectively for the 
period 1996 to 2005 (Fig. 7). The group of five countries is a major source of imports for Sub-
Saharan Africa providing more than 50% of import volume for that period.  Much of that trend is 
driven by India, which on average supplies 40% of the region’s imports each year. 
If we consider the percentage of imports based on trade value, the findings are similar. 
However, while high-income countries on average account for 43% of import volume, they account 
for almost 80% of imports in terms of trade value. Interestingly, for Latin America and the 
Caribbean, and Sub-Saharan Africa regions the percent of import value coming from high income 
countries is almost 8 times the percentage of imports coming from the group of five countries or 
other developing countries. This is despite the import quantity being almost the same. This is 
consistent with the expectation that imports from high-income countries are more expensive than 
those from developing countries. 
 
[Figure 7 about here] 
 
These trade trends provide evidence that China and India have become increasingly more 
important as sources of pharmaceutical imports for other low- and middle-income countries.  While 
Argentina, Brazil and Mexico also demonstrate a relatively high level of trade activity, they tend to 
be active only in their regional market. There are two preliminary conclusions we can draw from 
these trade trends. If middle-income countries do have a competitive effect on trade from high 
income countries, we would expect the greatest effect in Sub-Saharan Africa given that India is the   17 
largest supplier of pharmaceuticals on average. Second, of the five innovative developing countries 
India is likely to have the most pronounced effect because it is the only country with a leading 
market share relative to high-income countries as a trading block. We will therefore do a regression 
analysis focusing on the effect of imports from India and China on the average price of imports 
from high-income trading partners in the Sub-Saharan Africa region. We discuss our analysis in the 
proceeding sections.  
  
Model Estimation 
Given that Argentina, Brazil and Mexico export, on average, 1% or less of their 
pharmaceutical commodities to Sub-Saharan Africa, and trade the majority of their commodities 
within the regions, we have chosen to focus on India and China. Specifically, the regression analysis 
focuses on the effect of the share of pharmaceutical imports from China and India on the price of 
pharmaceutical imports from high-income trading partners. We employ the following model to 
estimate the effect: 
Pitc = β +δCIitc + γXit + Ψi + Ωc +Τt + ξitc  
Pitc is the average price per kilogram of commodity c imported from high-income trading partners by 
developing country i in year t, with t ranging from 1996-2005. CIitc  is the percent of drug imports 
from China and India by developing country i in year t; Xit  is a vector of country-level controls; Ψi 
represents country fixed effects; Ωc  represents commodity fixed effects and Τt represents year fixed 
effects.   
The dependent variable, Pitc is the mean annual price per kilogram of a given commodity 
imported by country i from high-income countries as a group.  Appendix I provides a list of the   18 
country groups based on economy and region. The dependent variable is constructed by aggregating 





,  where j is each high-income exporter. 
 
Table 1 shows the grouping for the commodities and Table 2 shows the descriptive statistics 
for the variables used in the regression models. Note that the commodity groups are very general 
and do not allow us to compare medicines that fall into specific therapeutic classes. As such each 
group contains a mix of both innovative, and hence expensive, drugs along with older and less 
expensive medicines. For example, the ‘other medicaments’ group will contain aspirin, a relatively 
non-expensive and ubiquitous commodity, as well as more innovative medicines such as cancer and 
HIV/AIDS therapeutics.  
We need to address an endogeniety issue that is inherent in the model. The same variables 
that help to determine the price of pharmaceutical imports from high-income countries may also 
influence the share of imports from China and India, CI, so that CI may be correlated with ξitc. We 
instrument for the share of imports from China and India to address this endogeneity issue.  A 
reasonable instrument will be correlated with CI but not with the mean price of pharmaceutical 
imports from high-income countries. In order to identify a suitable instrument we note that there 
are two factors that help to determine CI: (i) the existence of pharmaceuticals produced by China 
and India on the global market; (ii) and the existence of a trade relationship between these two 
countries and the importing country. The availability of medicines produced by China or India in a 
given country is conditional on the production of that medicine and its availability on the global 
market.   A reasonable instrument for the supply of medicines from China or India is therefore the   19 
percentage of medical imports worldwide from these countries to all countries excluding the country 
of interest.  We construct such a variable called PerGenElse. Existence of a trade relationship between 
two countries will also determine the extent to which they trade a particular commodity. We 
therefore lag CI as CIt-1 and CIt-2   and include them as an instrument.  The reasoning is that CIt-1 
and CIt-2  are measures of an existing relationship between the trading partners. We therefore expect 
the lagged variable to be correlated with CI   but not directly correlated with the dependent variable 
in year t.
8 So the first stage model was estimated using the following equation: 
CIitc = γ0 + γ1PerGenElseitc + γ2CIic(t-1) + γ3CIic(t-2) + vicrt  
One other variable related to the commodities is bulk, which represents the percent of 
imports for a particular commodity group that is imported in bulk form.  There are two types of 
pharmaceutical products, finished products which are packaged in dosage formulation and coded 
under the 3004 heading.  The second type is active ingredients which are intended to be used in the 
manufacture of a pharmaceutical product and as such packaged in bulk and not for retail sale and 
coded under the 3003 heading. Vaccines are not differentiated between finished and active 
ingredient formulation as shown in Table 1.  Vitamins are also coded only under the 3004 heading. 
It is expected that bulk products will be cheaper than the finished product which has gone through 
full production and dosage formulation. It is therefore important to account for the amount of the 
imported commodity group that is imported as active ingredient.  We accomplish this by including 
bulk, which represents the percent of imports for a particular commodity group as active ingredient 
(or traded under the 3003 heading).  
The model also includes a vector of control variables that attempt to account for the other 
factors that affect the prices of medicines. National GDP per capita is included as a measure of 
ability to pay.  GDP is often used as a criterion in preferential pricing schemes in which countries   20 
with a lower GDP are usually offered lower prices. Life expectancy (life), tuberculosis incidence (tb), 
infant mortality (infmort) and physicians-population ratio (physi) are included as indicators of the 
national disease profile and the demand for medicines. The model also includes country dummies to 
account for time-invariant country specific effects.  These variables control for other factors such as 
tariffs and procurement practices, which will affect the price of imports but are unlikely to vary over 
time. Year dummies are included to account for year-specific effects such as the licensing dispute in 
South Africa in 2001, which may have impacted medicine pricing negotiations and pharmaceutical 
procurement decisions across developing countries.  
 
Results and Discussion 
Column 1 of Table 3 presents the estimates for the effect of percentage imports from China 
and India (CI) on the average price of antibiotics and unspecified medicaments imported from high-
income trading partners.  Columns 2 and 3 show the same regression with the sample restricted to 
countries from the Asia and Pacific, Latin America and the Caribbean, and Sub-Saharan Africa 
regions. All the pharmaceutical commodities are included in column 3. As shown in columns 1 and 
2, the effect of the percentage imports from China and India is statistically significant and in the 
expected direction. This effect is no longer significant when we include the full sample of 
pharmaceutical commodities (Table 3, Column 3). This is not surprising because we know from 
examining the trends in the trade data that antibiotics and other medicaments account for 
approximately 90% of the pharmaceutical export volume for India and China.  
In terms of magnitude, the effect of the CI variable is strongest when the model is applied to 
the full sample of countries (Table 3, Column 1). On average, a one unit increase in the percent of 
imports from India and China will result in a 87-cents decrease in the average price of a 
pharmaceutical commodity imported from the high-income trading partners. While this may not 
seem like a substantial effect, it is important to put these numbers in context. Since the average price   21 
of antibiotics and unspecified medicaments from high income countries is around $40 (Table 2), on 
average prices fall by over 2 percent for each one percentage point increase in imports from China 
and India.  Emphasizing the importance of such savings, Niëns and colleagues (2010) have 
estimated the impoverishing effects of purchasing medicines out-of-pocket across 16 low- and 
middle-income countries.  In Uganda, for example, where 73% of the population subsists on less 
than US$2 per day, purchasing generic amoxicillin (a common antibiotic) has the potential to 
increase the proportion of the population below the poverty line (US$2 per day) to 74% compared 
to 86% if the originator brand is purchased (Niëns et al., 2010).  
 
[Table 3 about here] 
 
 
In terms of country characteristics, GDP and TB incidence are generally insignificant. This is 
not surprising given that both GDP and TB incidence do not show much variation from year to 
year. The effect of life expectancy is positive and significant in all three models (Table 3).
9 This 
suggests that countries with higher life expectancy tend to pay higher prices for their medicines. It is 
also possible that there is some collinearity between life expectancy and GDP in our model 
specification. Countries with higher life expectancy also have a higher ability to pay because of 
higher incomes. Further, income levels are one of the criteria used in preferential pricing to set lower 
prices for the least developed countries. Countries with lower income levels, and hence lower life 
expectancy, may therefore pay lower prices for their pharmaceutical imports.  
We also tested the effect of the percentage of imports from all five innovative middle-
income countries as an alternate key independent variable.  The results for this model are presented 
in Table 4, columns 1 and 2. While the sign on the coefficient is in the expected direction, the 
variable is insignificant and the magnitude smaller whether for the full panel of commodities 
(Column 1) or just antibiotics and medicaments (Column 2). The dummy variables for commodity   22 
type are also strongly significant with unspecified medicaments being cheaper than antibiotics, and 
antisera, vaccines and insulin being the most expensive commodity groups. However, note that our 
instruments do not perform as well in the full panel (column 1), as the p-value for Hansen’s J test is 
small, suggesting our instruments are not exogenous.  Given that Argentina, Brazil and Mexico trade 
the majority of their pharmaceutical commodities within the region and that antibiotics and 
medicaments account for the bulk of export volume for all five countries, our instruments appear to 
be picking up endogenous links between countries and commodities, rather than exogenous shifts in 
supply.
10  This is not a concern in column 2, however, where we once again limit the sample to those 
commodities most likely to be traded.  Here, the p-value for Hansen’s J test is greater than 0.1, and 
the F-statistic testing for weak instruments is large. 
We also tested the effect of imports from Argentina, Brazil and Mexico on the average prices 
of pharmaceutical imports from high-income trading partners in Latin American countries only. The 
results are shown in Table 4, columns 3 and 4.  Again we fail to observe a significant effect of 
import share.
11 Another possible explanation for the lack of significance is that the US dominated as 
the leading source of imports for much of the period under study and accounted for as much as 
60% of the import volume in 2002 before its annual market share started to decrease. The 
dominance of the market by one high-income producer suggests that the middle-income country 
producers are likely to have little effect at the regional level especially if the focus is on their 
domestic market. The patenting trends in Brazil, particularly if similar to those in other countries like 
Argentina, may also explain the lack of significance observed for all three alternate key independent 
variables for Latin America. As shown in Figure 2, all the high-income producers increased 
patenting after Brazil introduced its new patent laws in 1997.  However, the US, which dominated as 
a source of regional imports, had a disproportionate amount of patents granted relative to the other 
innovators.  This suggests that much of the regional trade is for generics of drugs off-patent or   23 
branded medicines produced by multinational subsidiaries or licensees, who can legally produce 
patented medicines.  Therefore, the group of medicines for which we would expect the biggest cost 
differences, generics of patented medicines, do not comprise a substantial portion of the market.  
The observations for the Latin American exporters are in contrast to the significant effect of 
imports from China and India in the Sub-Saharan Africa region (Table 3).  Again, both the patent 
and trade trends are consistent with this finding. When we consider the regional imports, note that 
India is the lead source of imports for Sub-Saharan, albeit not to the levels that the US was for Latin 
America and Caribbean region.  So India has a greater potential to compete with high-income 
producers.  It is also clear from the patent counts (Fig. 3) that domestic patents dominate the 
increasing trend in patents granted in India. Note that India did not become TRIPS-compliant until 
2005, so pharmaceutical patents on products were not allowed until 2005.  The increase in patent 
counts for India is therefore most likely from process patents.  This suggests that India 
pharmaceutical manufacturers could therefore legally produce generics for both off- and on-patent 
medicines for much of the period being studied.  This may therefore help to explain the significant 
effect we observe for imports from India and China. Indian manufacturers are able to trade in both 
on- and off-patent medicines therefore providing larger cost savings for consumers in that region. 
The regression results suggest that only pharmaceutical imports from China and India—and 
not all five innovative middle-income countries—have a significant effect on the average cost of 
pharmaceutical imports from high-income trading partners in developing countries. However, this 
effect is only observed for the antibiotics and unspecified medicaments and not the other 
commodity groups. This is not surprising as antibiotics and unspecified medicaments together 
account for 90% of the exports from China and India for the study period 1996 to 2005 and the 
bulk of overall pharmaceutical trade. The findings are also consistent with the trade data that show 
that China and India are the leading suppliers of medicines among the innovative middle-income   24 
countries, with Argentina, Brazil, Mexico only playing a regional role. It is likely therefore, that only 




The study provides evidence to support existing anecdotal evidence for the importance of 
China and India as suppliers of inexpensive medicines to other developing countries. While Latin 
America depends heavily on intraregional trade and imports from the U.S., Sub-Saharan Africa relies 
on India for 45% of its imports. As such, the enforcement of TRIPS is likely to have differing 
implications for the two regions. In Latin America where countries rely on domestic production and 
regional trade, they are likely to more easily invoke compulsory licenses and negotiate cheaper 
medicine prices as they can use their innovative capability as a bargaining tool.  However, this will be 
countered by the effect of more stringent intellectual property protection, which may limit the 
export market for pharmaceutical products from these countries and reduce potential cost savings 
regionally.  
The effect in the Sub-Saharan Africa region is likely to be more adverse. Most countries have 
until 2016 to become TRIPS-compliant but that is unlikely to have a direct effect on medicine prices 
as most countries in the region lack the innovative capability to reverse engineer innovative 
medicines for their domestic market.  However, given the importance of India as a supplier of 
inexpensive medicines, TRIPS is likely to negatively affect the availability of affordable medicines 
not only from India but also high-income trading partners through reduced competition from some 
generics.    
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1 There are existing studies that use private datasets but they tend to focus on prices in industrialized countries (Danzon 
& Furukawa, 2008; Danzon & Kim, 1998).  There is also the Health Action International drug price survey in 
collaboration with the WHO but they do not take the source of imports into account and focus on another important 
aspect of the issue, the differences at the point-of-purchase across select countries (Cameron, Ewen, Ross-Degnan, Ball, 
& Laing, 2009; WHO & HAI, 2003). 
2 As, of course, not all medicines imported from developing countries are generic copies of patented drugs, and not all 
imports from developed countries are branded drugs, our estimates provide a lower bound of the effect of generics on 
branded drugs. 
3 The term innovative developing countries refers to those countries that have the capability to reverse engineer innovative 
drugs.  We hope to draw a distinction between such countries and others that merely manufacture or repackage bulk 
formulations through local subsidiaries. 
4 A61P would allow us to find patents that are related to specific diseases. For example, A61P 31/06 for drugs that treat 
tuberculosis or A61P 33/06 for drugs that treat malaria.  Unfortunately, this subclass was introduced in the 7th and 8th 
(January 1, 2006) version of IPC and is therefore unavailable for earlier patents. We therefore use only subclass A61K to 
generate the patent counts, which does not allow for distinction between innovations for different illnesses without 
reading the bibliography of each patent. 
5 This is because the importer-reported trade values are recorded as cost, insurance and freight (CIF-type) value—
includes the transaction value of the goods, the value of services performed to deliver the goods to the border of the 
exporting country and top the border of the importing country.  The exporter-reported values on the other hand, are 
free-on-board (FOB-type) and only include the value of services performed to deliver the goods to the border of the 
exporting country (United Nations, 2004). 
6 We focus on patents granted in the US here because patent data from many individual developing country patent 
offices is incomplete.  Using the US data gives us complete coverage and focuses on patents applied for under a 
common set of patent laws. 
7 Unfortunately there are several noticeable gaps in the patent data, some of which have been documented by Inpadoc.  
Argentina for example, granted 35 patents in 1992 but none thereafter or in the preceding 1985-1991 period.  
8 Note that we also ran models based on imports from different combinations of the six middle-income countries.  In 
such cases we reconstruct our instruments using the correct combination of countries. 
9 For all the regressions presented in Tables 3 and 4, both infant mortality and physicians per capita were included 
together or separately as a measure of demand in other regressions (not shown).  However, their inclusion did not 
substantively change the estimates observed with life expectancy as a measure of demand. We therefore chose to use life 
expectancy for which we had a more complete panel of countries and years.  
10 In particular, pergenelse, which is intended to identify supply shifts, has almost no explanatory power in this model, with 
a t-statistic of just 0.08. 
11 Note that in column 4, where we only focus on antibiotics and medicaments, our instruments again perform poorly.  
We thus have less confidence in this result, but are comforted by the fact that import share is also insignificant in the full 
sample under column 3, where the instruments are valid.   26 
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Table 1. A description of the commodity classes from the Harmonized Classification System used to 







Antibiotics  300310  Medicaments containing penicillins, streptomycins or derivatives 
thereof, in bulk formulation 
300320  Medicaments containing antibiotics not elsewhere specified, in bulk 
formulation 
300410  Medicaments containing penicillins, streptomycins or derivatives 
thereof, in dosage formulation 
300420  Medicaments containing antibiotics not elsewhere specified, in 
dosage formulation 
Antisera  300210  Antisera and other blood fractions and modified immunological 
products 
Hormones  300339  Medicaments containing hormones not elsewhere specified, 
formulated in bulk 
300439  Medicaments containing hormones not elsewhere specified, in 
dosage formulation 
Insulin  300331  Medicaments containing insulin, formulated in bulk 
300431  Medicaments containing insulin, in dosage formulation 
Other 
Medicaments 
300340  Medicaments containing alkaloids or derivatives thereof but not 
containing hormones or antibiotics 
300390  Medicaments not elsewhere specified, formulated, in bulk 
300440  Medicaments containing alkaloids or derivatives thereof but not 
containing hormones or antibiotics, measured doses or packings for 
retail sale 
300490  Medicaments not elsewhere specified, in dosage 
Vaccines  300220  Vaccines, human use 
Vitamins  300450  Vitamins, derivatives, in dosage 
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Table 2. Descriptive statistics for the full sample of countries. 
 
Variable  Description  N  Mean  Std. Dev.  Min  Max 
Dependent Variable:           
Average 
Price 
Average price of 
imports sourced from 
high income countries 
(Constant 2000 US$) 
5884  $110.37  $203.91  $0.01  $4,965.64 
  Antibiotics  868  $43.31  $62.50  $0.01  $1,060.95 
  Antisera  803  $213.40  $329.86  $0.01  $4,158.51 
  Hormones  853  $85.98  $136.76  $0.01  $2,127.72 
  Insulin  779  $197.90  $248.90  $0.01  $4,965.64 
  Unspecified 
medicaments 
877  $35.36  $37.08  $0.01  $607.54 
  Vaccines  847  $186.72  $210.63  $0.01  $3,600.89 
  Vitamins  557  $27.78  $138.66  $0.01  $3,709.11 
Import Share  % of imports from 
China and India 




% of imports from 
China and India 
elsewhere 
5884  12.59%  11.43%  0.05%  61.16% 
% Bulk  % of imports in bulk 
formulation 
5884  8.77%  20.65%  0.01%  100% 
Antibiotics  Dummy variables for 
each commodity group 
5884  0.15  0.35  0  1 
Antisera    5884  0.14  0.34  0  1 
Hormones    5884  0.14  0.35  0  1 
Insulin    5884  0.13  0.34  0  1 
Medicaments    5884  0.15  0.36  0  1 
Vaccines    5884  0.14  0.35  0  1 
Vitamins    5884  0.15  0.35  0  1 
GDP  GDP per capita 
(constant 2000 US$) 
5847  $2,097.97  $1,941.93  $104.64  $8,961.25 
TB Incidence  Incidence of 
tuberculosis (per 
100,000 people) 
5884  152.65  164.09  4.87  1261.93 
Life 
Expectancy 
Life expectancy at birth 
(total years) 
5849  64.12  11.09  34.97  78.95 
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Table 3. Estimation results for the effect of imports from China and India on the average price of 
pharmaceutical commodities imported from high-income trading partners.  
 
Dependent Variable: Average price of pharmaceutical commodities from high-income trading partners 
Excluded Instruments: Pergenelse, Percent of imports from China and India lagged t-1 and t-2   
Explanatory Variables  (1)  (2)  (3) 
Import Share (CI)  -0.867*  -0.689*  0.347    
  (0.353)  (0.279)  (0.419)    
% Bulk  -0.073  -0.050  -0.360**  
  (0.091)  (0.095)  (0.110)    
GDP  0.004  0.003  0.038*** 
  (0.005)  (0.007)  (0.008)    
TB Incidence  0.075  0.028  0.060    
  (0.062)  (0.054)  (0.106)    
Life Expectancy  4.539*  2.335*  -2.742    
  (1.810)  (1.064)  (2.212)    
Medicaments  -7.849***  -4.876**  -5.535    
  (2.250)  (1.693)  (3.560)    
Antisera      115.138*** 
      (11.942)    
Hormones      34.274*** 
      (5.688)    
Insulin      128.376*** 
      (8.121)    
Vaccines      121.406*** 
      (7.135)    
Vitamins      -10.091    
      (8.082)    
Constant  -292.504*  -111.797  103.163    
  (127.682)  (92.310)  (146.246)    
N  1525  1075  3575    
R2  0.345  0.416  0.269    
Hansen J  4.274  2.865  3.386    
Hansen J p-value  0.118  0.239  0.184    
Kleibergen-Paap Wald F  10.939  8.984  42.275    
Standard errors in parentheses.  Significance: *p<0.05; **p<0.01; ***p<0.001 
Notes: Column 1 includes the full sample of countries; Columns 2 and 3 are limited to 
countries from the Asia and Pacific, Latin America and the Caribbean, and Sub-Saharan 
Africa regions, Column 3 includes all seven commodity groups. All models included year 
and country fixed effects. 
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Table 4. Estimation results for the effect of imports from Argentina, Brazil and Mexico on the 
average price of pharmaceutical commodities imported by countries in the Latin America and 
Caribbean region. 
 
Dependent Variable: Average price of pharmaceutical commodities from high-income trading partners 
Excluded Instruments  
 
Pergenelse, Percent of imports from Argentina, 
Brazil, China, India and Mexico lagged t-1 and 
t-2 
Pergenelse, Percent of imports from Argentina, 
Brazil and Mexico lagged t-1 and t-2 
Explanatory Variables  (1)  (2)  (3)  (4) 
Import Share (ABM)  -0.106  -0.312     -0.535  0.239    
  (0.407)  (0.200)     (0.668)  (0.150)    
% Bulk  -0.312  -0.069     -0.333  -0.224*   
  (0.182)  (0.090)     (0.189)  (0.103)    
GDP  0.021*  0.004     -0.002  -0.012    
  (0.011)  (0.005)     (0.019)  (0.008)    
TB Incidence  0.036  0.054     -0.174  -0.125    
  (0.114)  (0.060)     (0.198)  (0.068)    
Life Expectancy  -3.208  3.743*    -11.713  -1.302    
  (3.714)  (1.645)     (15.697)  (1.739)    
medicaments  -9.362*  -7.718***  -6.966  -6.070**  
  (4.218)  (2.091)     (5.421)  (2.127)    
antisera  164.586***                   110.101***                  
  (14.018)                   (21.435)                  
hormones  42.481***                   35.095***                  
  (6.242)                   (6.608)                  
insulin  155.010***                   155.894***                  
  (7.629)                   (9.641)                  
vaccines  140.125***                   116.918***                  
  (10.399)                   (13.799)                  
vitamins  -21.086*                   -5.199                  
  (8.330)                   (19.890)                  
Constant  188.297  -248.715*    871.153  154.796    
  (272.410)  (118.245)     (1118.373)  (133.991)    
N  4856  1457     1408  415  
R2  0.273  0.344     0.218  0.505    
Hansen J  8.580  4.409     4.060  7.850    
Hansen J p-value  0.014  0.110     0.131  0.020    
Kleibergen-Paap Wald F  90.924  18.570     61.206  36.007    
Standard errors in parentheses.  Significance: *p<0.05; **p<0.01; ***p<0.001 
Notes: Column 1 includes the full sample of countries; Column 2 is limited to countries from the Asia and Pacific, 
Latin America and the Caribbean, and Sub-Saharan Africa regions.  Columns 3 & 4 are restricted to just Latin 
America and Caribbean countries but differ in the commodity groups included in the model. All models included 
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Figure 1. Trends in patenting in the US among innovators from leading developing countries in the 
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Figure 2. Trends in patents granted in Brazil to foreign inventors, 1986-2006.  Only the top six 
countries are included. 
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Figure 3. Trends in patents granted in India to foreign inventors, 1987-2003.  Only the top six 
countries are included. 























































Figure 4. The regional markets for pharmaceutical exports from high-income countries (as a group), 
Argentina, Brazil, China, India and Mexico, 1996 to 2005.   
 
(NOTE: A&P = Asia & Pacific; E&CA = Europe and Central Asia; HIC = High income countries; 
LA&C = Latin America & Caribbean; ME&NA = Middle East and North Africa; SSA = Sub-
Saharan Africa) 
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Figure 5. Trends in pharmaceutical exports from China to regional markets, 1996 to 2005. 
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Figure 6. Trends in pharmaceutical exports from India to regional markets, 1996-2005. 

















































Figure 7. The source of pharmaceutical imports for each region, 1996-2005. 
 
(NOTE: A&P = Asia & Pacific; E&CA = Europe and Central Asia; HIC = High income countries; 
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Appendix I. Country groups based on region and economy. 
 
High Income       
Andorra  China, Macao SAR  Israel  Qatar 
Anguilla  Cyprus  Italy  Rep. of Korea 
Antigua and Barbuda  Denmark  Japan  Saudi Arabia 
Australia  Finland  Kuwait  Singapore 
Austria  France  Luxembourg  Slovenia 
Bahamas  French Polynesia  Malta  Spain 
Bahrain  Germany  Netherlands  Sweden 
Belgium  Greece  New Caledonia  Switzerland 
Bermuda  Greenland  New Zealand  USA 
Brunei Darussalam  Iceland  Norway  United Arab Emirates 
Canada  Ireland  Portugal  United Kingdom 
China, Hong Kong 
SAR 
     
Asia and Pacific Region  
Bangladesh  Indonesia  Nepal  Thailand 
Bhutan  Kiribati  Pakistan  Timor-Leste 
Cambodia  Malaysia  Philippines   
Fiji  Mongolia  Sri Lanka   
Middle East & North Africa 
Algeria  Jordan  Oman  Yemen 
Egypt  Lebanon  Syria   
Iran  Morocco  Tunisia   
Latin America & the Caribbean 
Argentina  Ecuador  Jamaica  Saint Kitts and Nevis 
Belize  El Salvador  Mexico  Saint Lucia 
Bolivia  Grenada  Nicaragua  Vincent and the 
Grenadines 
Chile  Guatemala  Panama  Suriname 
Colombia  Guyana  Paraguay  Uruguay 
Costa Rica  Honduras  Peru  Venezuela 
Dominica       
Sub-Saharan Africa 
Benin  Ethiopia  Mauritius  Sierra Leone 
Botswana  Gabon  Mozambique  South Africa 
Burkina Faso  Gambia  Namibia  Sudan 
Burundi  Ghana  Niger  Swaziland 
Cameroon  Guinea  Nigeria  Tanzania 
Cape Verde  Kenya  Rwanda  Togo   41 
Central African Rep.  Madagascar  Sao Tome and 
Principe 
Uganda 
Comoros  Malawi  Senegal  Zambia 
Cote d'Ivoire  Mali  Seychelles  Zimbabwe 
Eritrea  Mauritania     
Note: Based on the World Bank’s Country Classification available at http://go.worldbank.org/K2CKM78CC0. 
 
 
 
 